我的购物车

Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Monomer, MALS verified)

用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

  • 分子别名(Synonym)

    HLA-A*02:01 & B2M & NY-ESO-1

  • 表达区间及表达系统(Source)

    Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (HL1-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQC).

    Predicted N-terminus: Gly 25 & Ser

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa and 13.8 kDa. The protein migrates as 40-43 kDa and 13 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Biotin

  • 标记(Labeling)

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    95% as determined by SDS-PAGE.

    90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    HLA-A*02:01 & B2M & NY-ESO-1 SDS-PAGE

    Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%undefined.

  • SEC-MALS

    HLA-A*02:01 & B2M & NY-ESO-1 SEC-MALS

    The purity of Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) is more than 90% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     HLA-A*02:01 & B2M & NY-ESO-1 ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

    Protocol
  •  HLA-A*02:01 & B2M & NY-ESO-1 ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.0001-0.12 ng/mL (Routinely tested).

    Protocol
  • 活性(Bioactivity)-SPR

     HLA-A*02:01 & B2M & NY-ESO-1 SPR

    Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein (Cat. No. HL1-H82E6) with an affinity constant of 16.9 nM as determined in a SPR assay (Biacore 8K) (QC tested).

    Protocol

用户评价
发表评论

背景介绍

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQC peptide of the NY-ESO-1.

前沿进展

 
联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍